Across TCGA pan-cancer cohorts, ACTR3BP7 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated ACTR3BP7 data layer.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ACTR3BP7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ACTR3BP7 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

HNSC, STAD, and UVM are the cancer types where ACTR3BP7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.118	0.768	<.001	144	view →
STAD	DFS	Tertile	All	0.562	0.326	.024	18	view →
UVM	OS	Tertile	All	0.292	0.674	.035	18	view →
PCPG	DFS	Tertile	All	0.535	0.924	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ACTR3BP7 tumor-vs-normal RNA expression · all ACTR3BP7 data types